Advances in Urology

Clinical Study

Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)

Table 1

Baseline characteristics of subjects for short-term analysis set.
DemographicsImidafenacinSolifenacinP-value
Subjects1718
Age (years)(Mean ± SD) 7 0 . 2 ± 6 . 5 6 9 . 8 ± 7 . 7 0 . 8 6 9 7 a
 <60, n (%)0 (0%)1 (5.6%)
 ≥60, n (%)8 (47.1%)6 (33.3%)
 ≥70, n (%)9 (52.9%)11 (61.1%)
Gender
 Male, n (%)10 (58.8%)12 (66.7%) 0 . 7 3 3 2 b
 Female, n (%)7 (41.2%)6 (33.3%)
OABSS (total score)(Mean ± SD) 8 . 0 ± 2 . 0 8 . 7 ± 2 . 4 0 . 2 9 8 9 c
Severity of OABSS
 Mild, n (%)2 (11.8%)3 (16.7%) 1 . 0 0 0 0 c
 Moderate, n (%)15 (88.2%)14 (77.8%)
 Severe, n (%)0 (0%)1 (5.6%)
Postvoid residual volume (mL)(Mean ± SD) 1 4 . 2 ± 1 5 . 1 1 3 . 5 ± 1 1 . 4 0 . 8 8 1 4 a
Each urination volume (mL)(Mean ± SD) 1 4 1 . 7 ± 1 0 9 . 9 1 8 7 . 9 ± 1 6 0 . 8 0 . 3 3 1 2 a
Urination time (second)(Mean ± SD) 2 8 . 3 ± 1 9 . 8 2 7 . 4 ± 9 . 9 0 . 8 7 4 9 a
Qmax (mL/s)(Mean ± SD) 1 2 . 1 ± 7 . 4 1 4 . 2 ± 1 0 . 6 0 . 4 9 2 5 a
In male
 Prostate volume (mL)(Mean ± SD) 2 2 . 7 ± 1 1 . 6 2 5 . 3 ± 9 . 4 0 . 5 6 6 1 a
 Use of α1 blocker, n (%)9 (90%)9 (75%) 0 . 8 3 2 8 b
Severity of OAB was defined as total OABSS score ≤5: mild; 6 to ≤11: moderate; ≥12: severe
a: Unpaired t-test, b: Fisher’s exact test, c: Mann-Whitney U test, two-sided. SD: standard deviation.